A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified menotrophin [menotropins] versus recombinant FSH [follicle-stimulating hormone; follitropin alfa] administered subcutaneously to subfertile female patients undergoing IVF [in vitro fertilisation] using antagonist downregulation.

Trial Profile

A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified menotrophin [menotropins] versus recombinant FSH [follicle-stimulating hormone; follitropin alfa] administered subcutaneously to subfertile female patients undergoing IVF [in vitro fertilisation] using antagonist downregulation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Menotropin (Primary) ; Follitropin alfa
  • Indications Female infertility
  • Focus Therapeutic Use
  • Acronyms PROSPECT
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated: DRKS00004075 German Clinical Trials Register.
    • 02 Mar 2010 Actual initiation date changed from Jul 2006 to Oct 2005 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top